Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Disease Interception: Myths, Mountains, and Mole Hills.

Hait WN, Lebowitz PF.

Cancer Prev Res (Phila). 2016 Aug;9(8):635-7. doi: 10.1158/1940-6207.CAPR-16-0049. Epub 2016 May 2.

2.

Transforming Cancer Prevention through Precision Medicine and Immune-oncology.

Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, Dannenberg AJ, Hait WN, Blackburn E, Davidson NE, Foti M, Lippman SM.

Cancer Prev Res (Phila). 2016 Jan;9(1):2-10. doi: 10.1158/1940-6207.CAPR-15-0406.

3.

Genomic complexity: a call to action.

Hait WN, Levine AJ.

Sci Transl Med. 2014 Sep 24;6(255):255cm10. doi: 10.1126/scitranslmed.3009148.

PMID:
25253671
4.

Surviving metabolic stress: of mice (squirrels) and men.

Hait WN, Versele M, Yang JM.

Cancer Discov. 2014 Jun;4(6):646-9. doi: 10.1158/2159-8290.CD-14-0114.

5.

Therapeutic targeting of autophagy in disease: biology and pharmacology.

Cheng Y, Ren X, Hait WN, Yang JM.

Pharmacol Rev. 2013 Aug 13;65(4):1162-97. doi: 10.1124/pr.112.007120. Print 2013. Review.

6.

AACR Cancer Progress Report 2012.

Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers CL, Schreiber SL, Spitz MR, Steeg PS.

Clin Cancer Res. 2012 Nov 1;18(21 Suppl):S1-100. doi: 10.1158/1078-0432.CCR-12-2891. Epub 2012 Sep 11. No abstract available.

7.

Phosphorylation of elongation factor-2 kinase differentially regulates the enzyme's stability under stress conditions.

Huber-Keener KJ, Evans BR, Ren X, Cheng Y, Zhang Y, Hait WN, Yang JM.

Biochem Biophys Res Commun. 2012 Jul 27;424(2):308-14. doi: 10.1016/j.bbrc.2012.06.112. Epub 2012 Jun 27.

8.

Forty years of translational cancer research.

Hait WN.

Cancer Discov. 2011 Oct;1(5):383-90. doi: 10.1158/2159-8290.CD-11-0196. Erratum in: Cancer Discov. 2011 Dec;1(7):627.

9.

AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.

Khleif SN, Doroshow JH, Hait WN; AACR-FDA-NCI Cancer Biomarkers Collaborative.

Clin Cancer Res. 2010 Jul 1;16(13):3299-318. doi: 10.1158/1078-0432.CCR-10-0880. Epub 2010 May 25.

10.

Anticancer drug development: the grand challenges.

Hait WN.

Nat Rev Drug Discov. 2010 Apr;9(4):253-4. doi: 10.1038/nrd3144.

PMID:
20369394
11.

Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition.

Cheng Y, Li H, Ren X, Niu T, Hait WN, Yang J.

PLoS One. 2010 Mar 16;5(3):e9715. doi: 10.1371/journal.pone.0009715.

12.

A role for p53 in the regulation of extracellular matrix metalloproteinase inducer in human cancer cells.

Zhu H, Evans B, O'Neill P, Ren X, Xu Z, Hait WN, Yang JM.

Cancer Biol Ther. 2009 Sep;8(18):1722-8. Epub 2009 Sep 6.

13.

Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy.

Wu H, Zhu H, Liu DX, Niu TK, Ren X, Patel R, Hait WN, Yang JM.

Cancer Res. 2009 Mar 15;69(6):2453-60. doi: 10.1158/0008-5472.CAN-08-2872. Epub 2009 Feb 24.

14.

Is anticancer drug development heading in the right direction?

Hambley TW, Hait WN.

Cancer Res. 2009 Feb 15;69(4):1259-62. doi: 10.1158/0008-5472.CAN-08-3786. Epub 2009 Feb 10.

15.

Targeted cancer therapeutics.

Hait WN, Hambley TW.

Cancer Res. 2009 Feb 15;69(4):1263-7; discussion 1267. doi: 10.1158/0008-5472.CAN-08-3836. Epub 2009 Feb 10. Review.

16.

The individualization of cancer therapy: the unexpected role of p53.

Hait WN, Yang JM.

Trans Am Clin Climatol Assoc. 2006;117:85-101; discussion 101. Review.

17.

Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells.

Jin W, Scotto KW, Hait WN, Yang JM.

Biochem Pharmacol. 2007 Sep 15;74(6):851-9. Epub 2007 Jun 17.

19.

Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells.

Alli E, Yang JM, Ford JM, Hait WN.

Mol Pharmacol. 2007 May;71(5):1233-40. Epub 2007 Feb 1.

20.

Elongation factor-2 kinase: its role in protein synthesis and autophagy.

Hait WN, Wu H, Jin S, Yang JM.

Autophagy. 2006 Oct-Dec;2(4):294-6. Epub 2006 Oct 3.

PMID:
16921268
21.

Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53.

Alli E, Yang JM, Hait WN.

Oncogene. 2007 Feb 15;26(7):1003-12. Epub 2006 Aug 14.

PMID:
16909102
22.

A matter of life or death (or both): understanding autophagy in cancer.

Hait WN, Jin S, Yang JM.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1961-5. Review. No abstract available.

23.

Elongation factor-2 kinase regulates autophagy in human glioblastoma cells.

Wu H, Yang JM, Jin S, Zhang H, Hait WN.

Cancer Res. 2006 Mar 15;66(6):3015-23.

24.

Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to Anoikis through inhibition of Bim.

Yang JM, O'Neill P, Jin W, Foty R, Medina DJ, Xu Z, Lomas M, Arndt GM, Tang Y, Nakada M, Yan L, Hait WN.

J Biol Chem. 2006 Apr 7;281(14):9719-27. Epub 2006 Jan 27.

25.

Sustaining the clinical in clinical translational research.

Hait WN.

Clin Cancer Res. 2006 Jan 1;12(1):1-2. No abstract available.

26.
27.

Updated methods for reporting clinical trials.

Hait WN.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6753-4. No abstract available.

28.

Tubulin-targeting agents.

Hait WN, Rubin E, Goodin S.

Cancer Chemother Biol Response Modif. 2005;22:35-59. Review. No abstract available.

PMID:
16110607
29.

The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer.

Miletti-González KE, Chen S, Muthukumaran N, Saglimbeni GN, Wu X, Yang J, Apolito K, Shih WJ, Hait WN, Rodríguez-Rodríguez L.

Cancer Res. 2005 Aug 1;65(15):6660-7.

30.

People of the year. William N. Hait, MD, PhD. Interview by Bill Berlin.

Hait WN.

N J Med. 1998 Dec;95(12):26, 29. No abstract available.

PMID:
16013132
33.

Tubulin-targeting agents.

Hait WN, Rubin E, Goodin S.

Cancer Chemother Biol Response Modif. 2003;21:41-67. Review. No abstract available.

PMID:
15338740
34.

P-glycoprotein mediates resistance to histidine kinase inhibitors.

Arora S, Yang JM, Utsumi R, Okamoto T, Kitayama T, Hait WN.

Mol Pharmacol. 2004 Sep;66(3):460-7.

35.

Regulation of the stability of P-glycoprotein by ubiquitination.

Zhang Z, Wu JY, Hait WN, Yang JM.

Mol Pharmacol. 2004 Sep;66(3):395-403.

36.

Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma.

Alsina J, Gorsk DH, Germino FJ, Shih W, Lu SE, Zhang ZG, Yang JM, Hait WN, Goydos JS.

Clin Cancer Res. 2003 Dec 15;9(17):6419-25.

37.

Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines.

Arora S, Yang JM, Kinzy TG, Utsumi R, Okamoto T, Kitayama T, Ortiz PA, Hait WN.

Cancer Res. 2003 Oct 15;63(20):6894-9.

38.

Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide.

Grzywacz MJ, Yang JM, Hait WN.

Cancer Res. 2003 May 15;63(10):2492-8.

39.

Tubulin-targeting agents.

Hait WN, Rubin E, Goodin S.

Cancer Chemother Biol Response Modif. 2002;20:71-97. Review. No abstract available.

PMID:
12703201
40.

Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells.

Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN.

Mol Cancer Res. 2003 Apr;1(6):420-7.

43.

Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.

Alli E, Bash-Babula J, Yang JM, Hait WN.

Cancer Res. 2002 Dec 1;62(23):6864-9.

44.

Augmentation of apoptosis by the combination of bleomycin with trifluoperazine in the presence of mutant p53.

Sullivan GF, Garcia-Welch A, White E, Lutzker S, Hait WN.

J Exp Ther Oncol. 2002 Jan-Feb;2(1):19-26.

PMID:
12415616
45.

A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4.

Bash-Babula J, Toppmeyer D, Labassi M, Reidy J, Orlick M, Senzon R, Alli E, Kearney T, August D, Shih W, Yang JM, Hait WN.

Clin Cancer Res. 2002 May;8(5):1057-64.

46.
47.

Tubulin targeting agents.

Hait WN, Rubin E, Goodin S.

Cancer Chemother Biol Response Modif. 2001;19:59-83. Review. No abstract available.

PMID:
11686034
48.
49.

The prognostic and predictive values of ECD-HER-2.

Hait WN.

Clin Cancer Res. 2001 Sep;7(9):2601-4.

50.

Supplemental Content

Support Center